Harmonizing PD-L1 testing in metastatic triple negative breast cancer

Click to increase image sizeClick to decrease image size

Declaration of interests

P Tarantino served as advisor/consultant for AstraZeneca. J Cortes has declared consulting role for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, MSD, GlaxoSmithKline (GSK), Leuko, Bioasis, and Clovis Oncology; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, MSD, and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GmbH–Servier Affaires, Bayer Healthcare, Eisai, F Hoffman-La Roche, Guardant Health, MSD, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London and intellectual property for MedSIR. HS Rugo reports funding for sponsored studies paid to the University of California San Francisco from Pfizer, Novartis, Lilly, Roche–Genentech, Macrogenics, OBI, Merck, Eisai, Immunomedics, Daiichi Sankyo, Seattle Genetics, and Odonate; travel support for educational meetings from Daiichi Sankyo, Mylan, Pfizer, Merck, AstraZeneca, Novartis, and Macrogenics; and consulting fees from Samsung and Puma, outside the submitted work. G Curigliano received honoraria for speaker, consultancy, or advisory rule from AstraZeneca, Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, Daiichi Sankyo, and Samsung. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

One of the peer reviewers declares speakers honoraria from MSD and Roche, advisor/consultant for MSD and Roche, and travel grants from Roche. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.